Clinical Research Study Finder

Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling.

Find a Clinical Research Study

131 - 135 of 135


 The purpose of this study is to investigate the safety and effectiveness of eltrombopag in treating children and adolescents with newlydiagnosed immune thrombocytopenia (ITP). Patients aged between 1 to <18 years with newly diagnosed ITP will be eligible to enroll if they consent to participate within ten days from diagnosis and have not received any prior therapy or if they have failed standard management and are within thefirst three months from diagnosis. If you choose to participate, you will be on study for about 1 year. You will be randomly assigned to receive thestudy drug eltrombopag or standard therapy. Participation in this study includes weekly procedures such as assessments, physical exams, review ofmedical records, blood draws and questionnaires for 12 weeks and then about monthly or less often for up to 1 year. 

RIZE Clinical Trial for Individuals with Hyperinsulinism

Our team is working on a clinical drug trial that involves giving you a study drug that is not FDA-approved called RZ358. The goal of the trial is to test the study drug safety, how your body processes the drug, how the drug affects your body, and see if it can increase your blood sugar. If you agree to take part, your participation will last for up to 27 weeks and include 4 weeks of screening, 8 weeks of treatment, and a 15 week follow-up period. It is possible that treatment with the study drug infusions may improve your blood sugar levels and/or reduce the use of other medication(s) to prevent hypoglycemia. For more information, contact us at

Cyclerion Study

The purpose of this research is to investigate study drug IW-6463 in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). IW-6463 is not approved by the U.S. Food and Drug Administration for any use.

The study period will last for approximately 75 days and will include at least 4 to 6 on-site visits at the Children’s Hospital of Philadelphia (CHOP), where participants will be provided the study drug and monitored for safety.

For more information, please contact Sara Nguyen at

Cardiac MRI in T2D

The purpose of this study is to let researchers use cardiac MRIs to see if there are early changes in the heart of people with Type 2 Diabetes in comparison with healthy people. Our research team is currently seeking healthy women between the ages of 18 and 21 years of age to ask if they will partner with us as we try to learn more about heart health in young people with Type 2 Diabetes. African American ancestry is a risk factor for type 2 diabetes, and we are looking for African American young women in particular.  Participants will be asked to make one visit to CHOP to undergo a fasting blood draw and a cardiac MRI. Participants will be compensated for their time in the study.

Humanized CART19 Phase 2 Trial

This purpose of this study isto determine the efficacy of humanized CD19 CAR  T cells (huCART19) in pediatric and youngadult patients with high-risk relapsed or refractory B-cell acute lymphoblasticleukemia (B-ALL). You may be eligible to participate if you are between theages of 1-29 years with CD19-expressing B-ALL that is refractory tochemotherapy, has relapsed in the bone marrow <36 months from diagnosis,relapsed more than once, or relapsed after bone marrow transplant or afterprevious CAR T cell therapy. This study involves the administration of thestudy drug, blood draws, assessment of leukemia response, chart reviews, andquestionnaires. Reimbursement for travel may be provided. If you have questionsor would like to learn more about the study, please contact the CancerImmunotherapy Program at (215) 425-7193. The Principal Investigator is Dr. ShannonMaude and the Immunotherapy Nurse Navigator is Brooke Leibfreid, RN.